日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Prophylactic self-assembled nucleic acid hydrogel targeting retinal ganglion cell cuproptosis and microglial neuroinflammation for retinal ischemia-reperfusion injury

预防性自组装核酸水凝胶靶向视网膜神经节细胞凋亡和微胶质细胞神经炎症,用于治疗视网膜缺血再灌注损伤

Liu, Siwei; Wang, Zhongyu; Wu, Yue; Ju, Yahan; Tang, Zhimin; Zhang, Dandan; Chen, Xirui; Wang, Ning; Song, Mingyang; Gu, Cao; Liu, Yan; Guo, Wenyi; Zhang, Jing; Xiao, Caiwen; Lu, Linna; Zhang, Chuan; Ni, Ni; Gu, Ping

From Barrier to Gateway: Nanomaterials Reshaping the Tumor Microenvironment for Therapy

从屏障到门户:纳米材料重塑肿瘤微环境以促进治疗

Xie, Mina; Sun, Wanyu; Hu, Dongping; Liu, Lu; Han, Caiwen; Liu, Wenhan; Liu, Lede; Bao, Xiaojiang; Zhang, Weisheng; Hao, Xiangyong; Zhou, Yongqiang

HDACs targeting from traditional Chinese medicine: mechanisms and therapeutic potential in rheumatoid arthritis

来自传统中药的HDAC靶向疗法:在类风湿性关节炎中的作用机制和治疗潜力

Sun, Caiwen; Lv, Shaowa

Final Efficacy and Safety Results of Pyrotinib Combined With Trastuzumab and Chemotherapy in Pre-Treated Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer

吡咯替尼联合曲妥珠单抗和化疗治疗既往接受过治疗的人表皮生长因子受体2阳性转移性乳腺癌的最终疗效和安全性结果

Xie, Xiaofeng; Huang, Daijia; Huang, Jiayi; Chen, Xuelian; Bai, Xue; Zheng, Wenyu; Chen, Liping; Lan, Xiaofeng; Song, Lin; Lei, Rongmei; Du, Caiwen

Efficacy and safety of eribulin plus gemcitabine as second-line treatment for recurrent HER2-negative breast cancer: a phase II, single-arm, open-label trial

艾立布林联合吉西他滨作为复发性HER2阴性乳腺癌二线治疗的疗效和安全性:一项II期、单臂、开放标签试验

Xu, Xiaolu; Zhong, Jincai; Lin, Hong; Wang, Hong; Ye, Jinhui; Du, Caiwen; Wang, Zhihui; Zou, Guorong; Ouyang, Jie; Yu, Gengsheng; Wang, Yongxia; Li, Luzhen; Xu, Fei; Cui, Shien; Xiao, Mei; Peng, Peijian

Oral probiotic extracellular vesicle therapy mitigates Influenza A Virus infection via blunting IL-17 signaling

口服益生菌胞外囊泡疗法通过抑制IL-17信号传导减轻甲型流感病毒感染

Zhou, Hongxia; Huang, Wenbo; Li, Jieting; Chen, Peier; Shen, Lihan; Huang, Wenjing; Mai, Kailin; Zou, Heyan; Shi, Xueqin; Weng, Yunceng; Liu, Yuhua; Yang, Zifeng; Ou, Caiwen

Silicified curcumin microspheres Combats cardiovascular diseases via Nrf2/HO-1 pathway.

硅化姜黄素微球通过Nrf2/HO-1通路对抗心血管疾病

Guan Tianwang, Lu Zhenxing, Tai Rundong, Guo Shuai, Zhang Zhaowenbin, Deng Shaohui, Ye Jujian, Chi Kaiyi, Zhang Binghua, Chen Huiwan, Deng Zhilin, Ke Yushen, Huang Andong, Chen Peier, Wang Chunming, Ou Caiwen

NEXN protects against vascular calcification by promoting SERCA2 SUMOylation and stabilization.

NEXN 通过促进 SERCA2 SUMO 化和稳定来防止血管钙化

Guo Wenjie, Guo Wenjing, Chen Boliang, Lin Zexuan, Wen Zhuohua, Ye Jiamin, Feng Wei, Feng Xin, Yan Jianyun, Yang Pingzhen, Ouyang Kunfu, Li Yifei, Yang Hanyan, Ou Caiwen, Liu Canzhao

Understanding the gap between expectations and reality in decentralized clinical trials

了解分散式临床试验中预期与现实之间的差距

Jiang, Yale; Leng, Ye; Wu, Qing; Hou, Yiru; Dong, Xueyuan; Zeng, Caiwen; Wu, Dawei; Fang, Hong; Tang, Yu; Huang, Huiyao; Li, Ning

Targeting KAT7 inhibits the progression of colorectal cancer

靶向KAT7可抑制结直肠癌的进展

Wang, Hao; Guan, Tianwang; Hu, Rong; Huang, Zhongjie; Liang, Zhao; Lin, Xiaonan; Qiu, Yingqi; Liao, Peiyun; Guo, Xiongbo; Ke, Yushen; Zhang, Honghao; Ou, Caiwen; Li, Yuhua